Dr. Soon Sing Yang, Secretary General, and Chair, Memberships

Professional Designation	Professor & Consultant
Department	Cardiothoracic Surgery
Organization of Employment	Sarawak Heart Center, Kuching Borneo Medical Centre, Kuching KPJ Kuching Specialist Hospital, Kuching Timberland Medical Centre, Kuching Normah Medical Specialist Centre, Kuching
Academic and Non-Academic Appointments	Founding Board Member of the South East Asian Thoracic Society and currently serves as Chair of the SEATS School of Thoracic Surgery. Examiner, Royal College of Surgeons Edinburgh (RCSEd) Trainer, Malaysia Cardiothoracic Fellowship Training Programme

Profile

Prof. Soon Sing Yang is the Secretary General, and Chair of Memberships of ATA. Prof. Soon is also a Founding Board Member of the South East Asian Thoracic Society and currently serves as Chair of the SEATS School of Thoracic Surgery. He is the pioneer and lead for the Malaysia Lung Cancer Registry and acts as an examiner for the Royal College of Surgeons Edinburgh (RCSEd). As a proctor in VATS Surgery and TEVAR, he plays a vital role in advancing minimally invasive techniques.

Additionally, Dr. Soon is a trainer for the Malaysia Cardiothoracic Fellowship Training Programme and has contributed as an investigator or sub-investigator in multiple Phase 3 randomized trials. He has also authored numerous peer-reviewed publications and textbook chapters. His expertise is recognized internationally, as he frequently serves as invited faculty at various international congresses and societies.

Education

MBCHB, University of Edinburgh, UK
Specialist Degree, FRCSED (C-TH), ROYAL COLLEGE OF SURGEONS, EDINBURGH, UK
INTERCOLLEGIATE EXAMINATION IN CARDIOTHORACIC SURGERY, CCT, UK

Recent & Current Appointments and Committee Memberships

Founding Board Member, South East Asian Thoracic Society
Chair, SEATS School of Thoracic Surgery
Pioneer and Lead, Malaysia Lung Cancer Registry
Examiner Royal College of Surgeons Edinburgh (RCSEd)
Proctor: VATS Surgery, TEVAR
Trainer, Malaysia Cardiothoracic Felllowship Training Programme
Investigator/Sub Investigators, Multiple Phase 3 Randomised Trials
Author, Multiple Peer Review publications and textbook chapters
Invited Faculty Multiple International Congresses/Society

2024, Does dose reduction of afatinib affect treatment outcomes in patients with EGFR mutant metastatic non small cell lung cancer in real world clinical practice? Transl Lung Cancer Res. Vol 13(2):307-320.
2023, Real-world treatment and outcomes of ALK positive metastatic non small cell lung cancer in a Southeast Asian Country. Cancer Manag Res;15:31-41
2022, Programmed death ligand1 expression & use of immune check point in patients with advanced non small cell lung cancer in Malaysia. Thoracic Cancer. Vol 13(11):1676-1683.
2022, Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia. Cancer Manag Res. 16;14:1995-2005
2020, Lung Cancer in Malaysia. Journal of Thoracic Oncology. Vol 15(3): 317-323

2024: International phase 3 randomised trial “INTerpath-002” investigating the use of adjuvant Individualised Neoantigen Therapy with Pembrolizumab in patients with stage 2 to 3b resected NSCLC.
2023: International phase 3 trial “Target” investigating the use of adjuvant osimiternib over 5 years in patients with stage 2 to 3b EGFR positive NSCLC.
2023: International phase 3 trial “Adaura 2” investigating the use of osimertinib in stage 1A2 or A3 patients with EGFR positive NSCLC.
2021: International Phase 3 randomised Trial “Keynote 671” investigating the use of peri-operative immunotherapy in patients with resectable lung cancer.